Body Composition in Anti-Obesity Medication Trials-Beyond Scales.
作者信息
Agarwal Ank A, Narayan Aditya, Stanford Fatima Cody
机构信息
Stanford University School of Medicine, Palo Alto, California.
Neuroendocrine Unit, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Boston.
出版信息
JAMA Intern Med. 2024 Apr 1;184(4):341-342. doi: 10.1001/jamainternmed.2023.7733.
Abstract
摘要
相似文献
1
Body Composition in Anti-Obesity Medication Trials-Beyond Scales.
JAMA Intern Med. 2024 Apr 1;184(4):341-342. doi: 10.1001/jamainternmed.2023.7733.
2
[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].
Ugeskr Laeger. 2009 Oct 5;171(41):2974-7.
3
The safety and efficacy of lorcaserin in the management of obesity.
Postgrad Med. 2013 Nov;125(6):62-72. doi: 10.3810/pgm.2013.11.2713.
4
Long-term pharmacotherapy for obesity and overweight.
Cochrane Database Syst Rev. 2003(4):CD004094. doi: 10.1002/14651858.CD004094.
5
Long-term pharmacotherapy for obesity and overweight.
Cochrane Database Syst Rev. 2004;2003(3):CD004094. doi: 10.1002/14651858.CD004094.pub2.
6
The effect of obesity pharmacotherapy on body composition, including muscle mass.
Int J Obes (Lond). 2025 Mar;49(3):381-387. doi: 10.1038/s41366-024-01533-3. Epub 2024 May 14.
7
Rimonabant for overweight or obesity.
Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD006162. doi: 10.1002/14651858.CD006162.pub2.
8
Regular Consumption of Lipigo Promotes the Reduction of Body Weight and Improves the Rebound Effect of Obese People Undergo a Comprehensive Weight Loss Program.
Nutrients. 2020 Jun 30;12(7):1960. doi: 10.3390/nu12071960.
9
Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
Diabetes Obes Metab. 2000 Apr;2(2):105-12. doi: 10.1046/j.1463-1326.2000.00071.x.
10
Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.
Fam Pract. 2023 Dec 22;40(5-6):629-637. doi: 10.1093/fampra/cmac141.
引用本文的文献
1
Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose Depots.
Physiologia. 2025 Mar;5(1). doi: 10.3390/physiologia5010010. Epub 2025 Feb 27.
2
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Diabetes Obes Metab. 2025 May;27(5):2720-2729. doi: 10.1111/dom.16275. Epub 2025 Feb 25.
3
Mitigating muscle loss during weight loss: can nutritional ketosis make a difference? A call for more research.
Obesity (Silver Spring). 2025 Mar;33(3):431-434. doi: 10.1002/oby.24235. Epub 2025 Feb 13.
4
Nutritional and functional outcomes in trials of nutrient-stimulated hormone-based therapy-A systematic mapping review.
Obes Rev. 2025 May;26(5):e13890. doi: 10.1111/obr.13890. Epub 2025 Jan 27.
5
Fundamental Body Composition Principles Provide Context for Fat-Free and Skeletal Muscle Loss With GLP-1 RA Treatments.
J Endocr Soc. 2024 Sep 25;8(11):bvae164. doi: 10.1210/jendso/bvae164. eCollection 2024 Sep 26.
6
The Patient's Journey in Obesity within the United States: An Exercise of Resilience against Disease.
Life (Basel). 2024 Aug 27;14(9):1073. doi: 10.3390/life14091073.
7
A new framework for the diagnosis, staging and management of obesity in adults.
Nat Med. 2024 Sep;30(9):2395-2399. doi: 10.1038/s41591-024-03095-3.
8
Challenges With Relying on Body Fat and Weight Values for Obesity-Reply.
JAMA Intern Med. 2024 Aug 1;184(8):990-991. doi: 10.1001/jamainternmed.2024.2376.
本文引用的文献
1
Equity and Obesity Treatment - Expanding Medicaid-Covered Interventions.
N Engl J Med. 2023 Jun 22;388(25):2309-2311. doi: 10.1056/NEJMp2303268. Epub 2023 Jun 17.
2
The Challenge of Defining the Optimal Lifestyle Weight Loss Intervention for Real-world Settings.
JAMA. 2022 Dec 13;328(22):2213-2214. doi: 10.1001/jama.2022.21908.
3
A call for solutions for healthy aging through a systems-based, equitable approach to obesity.
J Am Geriatr Soc. 2022 May;70(5):1599-1604. doi: 10.1111/jgs.17732. Epub 2022 Mar 9.
4
Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution.
BJR Case Rep. 2019 Mar 14;5(3):20170078. doi: 10.1259/bjrcr.20170078. eCollection 2019 Sep.
5
Obesity Pathogenesis: An Endocrine Society Scientific Statement.
Endocr Rev. 2017 Aug 1;38(4):267-296. doi: 10.1210/er.2017-00111.
Zotero 插件